Screening for Early Functional Visual Decline Using Multidomain Ocular Assessment

Abstract

Early detection of functional visual decline is crucial for preventing irreversible vision loss and improving patient outcomes. Multidomain ocular assessment tools have emerged as promising approaches to identify subtle deficits in visual function before structural changes become evident. This review critically examines the current landscape of screening methodologies, epidemiological data, underlying pathophysiological mechanisms, risk factors, clinical features, diagnostic strategies, treatment paradigms, recent advances, and guideline-based recommendations for early functional visual decline, emphasizing the integration of multidomain assessment techniques in clinical practice.

Introduction

Functional visual decline often precedes overt structural changes in a range of ocular diseases, including glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy. Traditional screening modalities frequently overlook early deficits, resulting in missed opportunities for intervention. Multidomain ocular assessment combining psychophysical, electrophysiological, and imaging modalities offers a comprehensive approach to detect preclinical functional impairment. This article synthesizes the latest scientific evidence on the utility of multidomain assessment in screening for early visual decline, aiming to provide actionable insights for clinicians and eye care professionals.

Epidemiology / Disease Burden

The global burden of visual impairment continues to rise, with over 2.2 billion people estimated to experience some form of visual disability. Of these, at least one billion cases are preventable or have yet to be addressed. Early functional visual decline is particularly prevalent among aging populations and individuals with systemic comorbidities such as diabetes and hypertension. Epidemiological studies reveal that up to 50% of glaucoma cases remain undiagnosed until advanced stages, underscoring the limitations of current screening strategies and the potential impact of more sensitive, multidomain approaches.

Pathophysiology

Functional visual decline arises from disruptions in the retinal neurovascular unit, phototransduction pathways, and higher-order visual processing centers. In glaucoma, early dysfunction of retinal ganglion cells and their synapses occurs well before detectable optic nerve head changes. AMD is characterized by the progressive loss of photoreceptor function, with dark adaptation abnormalities preceding anatomical degeneration. Diabetic retinopathy involves microvascular compromise leading to retinal hypoxia and subsequent functional impairment, even in the absence of overt hemorrhages or edema. These pathophysiological insights highlight the necessity of functional testing alongside structural assessment.

Risk Factors

Key risk factors for early functional visual decline include advanced age, family history of ocular disease, metabolic syndrome, poor glycemic control, hypertension, and prolonged exposure to environmental stressors such as ultraviolet light and smoking. Genetic predispositions, particularly in primary open-angle glaucoma and AMD, further elevate risk. The presence of systemic neurodegenerative conditions, such as Alzheimer's disease, has also been correlated with patterns of functional visual decline, supporting the concept of eye-brain axis involvement in early disease manifestation.

Clinical Features

Patients with early functional visual decline may report subtle symptoms such as reduced contrast sensitivity, impaired dark adaptation, difficulty with glare, or mild reading difficulties, despite preserved visual acuity. These complaints are often non-specific and can be easily overlooked during routine examinations. Objective findings may include diminished performance on contrast sensitivity tests, color vision abnormalities, or defects on perimetry that do not correspond to structural changes on fundus examination or optical coherence tomography (OCT).

Diagnosis

Comprehensive diagnosis of early functional visual decline requires a multidomain approach. Psychophysical assessments, including contrast sensitivity, color vision, and dark adaptation tests, are essential for capturing subtle functional impairments. Advanced perimetry techniques, such as frequency-doubling technology (FDT) and short-wavelength automated perimetry (SWAP), enhance detection sensitivity. Electrophysiological measures pattern electroretinogram (PERG) and multifocal visual evoked potentials (mfVEP) provide objective evidence of retinal and post-retinal dysfunction. Structural imaging with OCT and fundus autofluorescence remains complementary, helping to correlate functional deficits with anatomical changes. Integration of artificial intelligence (AI)-based analysis further augments diagnostic accuracy by recognizing complex patterns across domains.

Treatment & Management

Management of early functional visual decline focuses on modifiable risk factor optimization and disease-specific interventions. In glaucoma, intraocular pressure (IOP) reduction through pharmacological or procedural means is initiated even in pre-perimetric cases when functional impairment is demonstrated. Early AMD management emphasizes lifestyle modification, antioxidant supplementation, and, in select cases, investigational pharmacotherapies. Diabetic patients benefit from stringent glycemic and blood pressure control. Visual rehabilitation strategies, including low vision aids and adaptive training, may be introduced even at early stages to preserve quality of life.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of portable, user-friendly devices for home-based visual function monitoring, expanding access to screening. AI-driven analysis of multidomain data sets enables earlier and more precise identification of at-risk individuals. Pharmacologic neuroprotection, retinal implants, and gene therapies are under investigation for their potential to preserve or restore function in early disease. Additionally, population-based screening initiatives leveraging telemedicine and cloud platforms are improving outreach, particularly in underserved regions.

Guideline Recommendations

Major ophthalmological societies now advocate for the inclusion of functional testing in routine screening protocols for high-risk populations. The American Academy of Ophthalmology (AAO) recommends contrast sensitivity and perimetry in addition to structural imaging for glaucoma and AMD suspects. The European Glaucoma Society underscores the value of integrating PERG and FDT perimetry for early diagnosis. Personalized risk stratification based on multidomain assessment is increasingly endorsed as a standard of care, promoting tailored surveillance and intervention.

Conclusion

Early functional visual decline often precedes irreversible structural damage and vision loss in major ocular diseases. Multidomain ocular assessment, encompassing psychophysical, electrophysiological, and imaging modalities, represents a paradigm shift in screening and early detection. Ongoing advances in technology and data analytics are poised to further refine these approaches, enabling earlier intervention and improved clinical outcomes. Incorporation of multidomain assessment into routine practice is supported by current evidence and guidelines, offering significant promise in mitigating the global burden of preventable visual impairment.